Opinion|Videos|November 18, 2026

Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence

B-cell depletion moves treatment upstream but may require more time to achieve its full clinical effect. FcRn therapy can provide a potential bridge when faster disease control is needed.

In ‘Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence,’ our panel explores how B-cell–directed therapies fit into the expanding treatment sequence for myasthenia gravis. Faculty contrast these upstream approaches with therapies that act on circulating pathogenic antibodies or downstream effector mechanisms. They discuss CD20-directed rituximab and CD19-directed inebilizumab, noting that the optimal positioning of B-cell depletion can differ according to antibody subtype, prior therapy, and the available clinical evidence.

The experts highlight MuSK-positive MG as an important example in which B-cell–directed therapy may be prioritized because of the underlying biology of antibody production. They also discuss emerging questions about whether earlier B-cell depletion in acetylcholine receptor–positive disease could alter disease trajectory. At the same time, the panel emphasizes the slower onset of B-cell–directed therapies. Clinical benefit may continue to develop over several months, meaning that patients with active symptoms may need additional treatment while waiting for the full effect.

This creates a potential role for FcRn-targeted therapy as a bridge. Faculty describe using faster-acting FcRn inhibition to maintain control while a slower B-cell–directed strategy becomes effective, particularly when corticosteroid bridging is undesirable. The duration of this bridge depends on the expected onset of the B-cell therapy and the patient's individual response. Once adequate control from B-cell depletion emerges, FcRn therapy may then be tapered or withdrawn.

Our next episode, ‘Tapering Combination Therapy After Minimal Symptom Expression in MG,’ will explore how clinicians simplify multidrug regimens once disease control is achieved, including careful corticosteroid tapering and reassessment of ongoing FcRn and conventional therapies.


Related to this article